Pfizer wraps InnoPharma buyout; Strides Arcolab agrees to Shasun pickup;

@FiercePharma: FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair. Story | Follow @FiercePharma

@TracyStaton: Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack. News | Follow @TracyStaton

@CarlyHFierce: Allergan buy Salix? Not so fast, say investors intent on Valeant vote. Article | Follow @CarlyHFierce

> Pfizer ($PFE) has completed its buyout of InnoPharma. Release

> India's Strides Arcolab has agreed to buy Shasun Pharma for $200 million in an all-stock deal. Report

> Baxter ($BAX) and Kamada have extended their supply agreement for emphysema drug Glassia. Release

> China is producing its first erectile dysfunction medicine treatment based on compound ingredients previously patented for Pfizer's ($PFE) Viagra. More

> CVS Caremark ($CVS) will pay $6 million to settle U.S. allegations that it knowingly failed to reimburse Medicaid for certain prescription drug costs. Report

Medical Device News

@FierceMedDev: Medtronic may revise $42.9B deal with Covidien under new tax rules. Story | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study #cancer nanomed delivery. More | Follow @MichaelGFierce

@VarunSaxena2: FierceMedicalDevices has learned that James V. Mazzo is on suspension as operating partner at life science VC Versant Ventures due to indictment. | Follow @VarunSaxena2

@EmilyWFierce: American Academy of Pediatrics backs IUDs as first-line choice for teens seeking long-term contraception. Article | Follow @EmilyWFierce

> Implanted pulley device could aid those with nerve damage to their hands. Story

> Court rules that FDA cannot rescind 510(k)s without notice and comment procedures. Article

Biotech News

@FierceBiotech: Just how big is the biosimilars business going to be in 5 years? Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Tiny biotech, trumpeting reformulation of a muscle relaxer, shotgun R&D strategy - what's not to like? $TNXP plunges. Story | Follow @JohnCFierce

@DamianFierce: There are now 245 companies developing biosimilars around the globe, according to @Reuters. Article | Follow @DamianFierce

@EmilyMFierce: New Washington player joins push for NIH funding. Story | Follow @EmilyMFierce

> Tonix shares battered as lead fibromyalgia drug flops in PhIIb. Article

> Daiichi Sankyo bags leukemia drug in $410M Ambit buyout. News

> ESMO: Bristol-Myers, Roche, AstraZeneca, GSK, Merck jostle for spotlight. Story

> Alimera and pSivida finally win FDA approval for thrice-rejected drug. More

CRO News

> Evotec lends its R&D might to the multiple sclerosis cause. More

> Catalent partners up with Cingulate on two ADHD drugs. Article

> Post-IPO Ergomed keeps rolling with its risk-sharing partnerships. Report

> AstraZeneca moves away from outsourcing, at least in IT. Item

> GVK accused of tampering with data in Indian clinical trials. Article

Biotech IT News

> Medidata stung by $4.8M wire transfer fraud. News

> NIH backs database-driven approach to neuromuscular research. Report

> The FDA commits $16M to track prescription drug use. Item

> PatientPowered.us wins PCORI clinical trial matchmaking app competition. Story

> FDA's Mini-Sentinel set to graduate on October 1. More

Animal Health News

> Merial expands NexGard plant in Brazil with $25M infusion. News

> Elanco and Dow AgroSciences team up to meet global demand for food. Article

> Avacta unveils new test for diagnosing lymphoma in dogs. Story

> Study: No differences between genetically engineered and non-GE feed on animals. More

> UN's Food and Agriculture Organization warns of new strain of avian influenza virus. Item

And Finally... Rising wealth in Asia is spurring more "diseases of the affluent," a hospital operator says. More

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.